Hints and tips:
...Bill Ackman’s exit from Valeant Pharmaceuticals has dealt a blow to another high-profile hedge fund manager, John Paulson, who is sitting on his own $2bn-plus loss on the healthcare stock....
...Valeant, the Canadian drugmaker, has also been targeted by Mrs Clinton, as has Martin Shkreli, who became an international pariah after increasing the price of a medicine given to Aids sufferers from $13.50...
...Funds may have sold out of Valeant, Apple et al before the rot set in....
...Maybe we will discover that many managers were smart enough to sell out of Apple, Valeant, Williams et al before their shares tanked....
...The deal comes less than two months after the Dublin-based group dropped out of its $10bn pursuit of Salix following a bidding war with Valeant....
...(Financial Times) Valeant Pharmaceuticals is preparing to take its bid for Allergan direct to shareholders after its latest $53bn offer was rejected by the maker of Botox....
...The deal will see Teva pay $81.50 a share, outgunning a $73 a share hostile approach for Cephalon made in March by Valeant . Shares in Valeant fell 5.8 per cent to $49.58 on the news....
International Edition